DaSH Global and Mesothelioma UK are delighted to announce the launch of an updated ‘Your Health Companion’ to support patients living with peritoneal mesothelioma within the UK and across the world. Your Health Companion is the first real-world data collection tool, designed specifically to support patients diagnosed with peritoneal mesothelioma
Peritoneal mesothelioma is a rare type of cancer (representing no more than 7-10% of all mesotheliomas) that affects the peritoneum, a membrane that lines the abdominal cavity and organs. Like other types of mesotheliomas, peritoneal mesothelioma can be related to prior exposure to asbestos.
Treatment for peritoneal mesothelioma can prolong life, and the disease can go through periods of remission. Your Health Companion for peritoneal mesothelioma has been co-developed with specialist peritoneal nurses, clinicians, and patient advocacy groups to enable people to keep an accurate record in one place, across time. This ensures they are better equipped to monitor changes in their health and wellbeing and allows them to share their information with their team to help improve treatment outcomes and quality of life.
Sam Westbrook, Meso UK’s lead Peritoneal Meso Nurse Specialist, who sits on the national Peritoneal Multi-Disciplinary Team (MDT) at Basingstoke Hospital with peritoneal malignancy consultant surgeons, radiologists, pathologists and oncologists says:
“Our mission has always been to improve the quality of life of patients living with peritoneal mesothelioma. As this disease is so rare, it is often difficult for patients to access targeted support directly for them and their condition. This tool will help them to live well, share their current condition with us, and help inform research into this condition.”
Liz Darlison, Chief Executive of Mesothelioma UK, who has spearheaded the development Your Health Companion for mesothelioma, confirms:
“Being able to gain continuous, accurate feedback directly from peritoneal mesothelioma patients will give us a more complete view of how this rare disease is impacting a population. We will be able to look in to the disease better to help us drive improvements in the treatments and support we can offer.”
DaSH Global is delighted to support long-term partner, Mesothelioma UK, to establish a national real-word patient research platform (The Digital Assessment Xchange) via the collection of Patient Reported Outcomes (PROMs) outside of clinical practice. The DAX platform is also part of a long-term multi-stakeholder strategy to enable the collection of PROMs in a real-world setting to assess the effectiveness of new medicines and the delivery of health services. By linking into national medical records, real-world studies can be undertaken to provide cost efficient, timely and precise evidence for the reimbursement and regulatory approval of new medicines.
“This new release of Your Health Companion in Peritoneal Mesothelioma confirms DaSH Global’s strategy to support patients to live well for longer, at the same time, providing ‘unique’ real-world data that can be used by pharma to accelerate research. Thus enabling them to meet the increasing regulatory & reimbursement demands that incorporates the patient voice into observational research .” Andrew Turner, Director and Founder, DaSH Global.
There are currently three versions of the companion available, one for lung cancers, pleural mesothelioma and now peritoneal mesothelioma. Through the ongoing set up of the DAX platforms DaSH Global are looking to enter new disease areas throughout 2024
